Microsoft is top provider of healthcare AI, report finds
A new report looking at artificial intelligence in healthcare has found that Microsoft comes top in terms of perceived strength of their AI solutions, ahead of IBM, Amazon and Google.
The report by healthcare data company KLAS Research, examined the recent AI purchase decisions of 47 organisations to determine which vendors are being considered and chosen, which are being replaced, and why.
Half of respondents who shared perceptions of Microsoft said they have a strong healthcare AI offering. Highlighting Microsoft’s healthcare partnerships (e.g., Microsoft Azure is leveraged by Epic, Health Catalyst, Jvion, and KenSci), organisations feel Microsoft has more healthcare expertise than the other cross-industry vendors.
Azure’s AI infrastructure and platform are integrated with other highly adopted Microsoft products, such as Office 365 and Teams, and respondents note that Microsoft seems to have better security and a strong data-protection guarantee.
Google is noted for advanced capabilities that allow customers to create algorithms capable of impacting patient outcomes, but they are not viewed as having a strong platform. Meanwhile Amazon is on the rise, while IBM is seen as some to over-promise and yield unsatisfactory results.
The report also highlights the importance of AI and ML for imaging, highlighting three purpose-built, FDA-approved imaging AI vendors who are emerging as early leaders: Aidoc, Viz.ai, and Zebra Medical Vision.
Current users of ClosedLoop.ai, DataRobot, Epic, Health Catalyst, Jvion, and KenSci shared their customer satisfaction levels for the survey, with KenSci client satisfaction remaining high while it has decreased for Health Catalyst and DataRobot.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”